Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia

Vasc Health Risk Manag. 2008;4(6):1439-47. doi: 10.2147/vhrm.s4001.

Abstract

Background: The present study was undertaken to investigate the effect of statins plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in South Asians with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary artery disease.

Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the first group and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week assessment of endothelial function and lipid profile.

Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: -1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition of omega-3-PUFAs further improved the lipid profile (triglycerides 139 to 91 mg/dl, p = 0.006, low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014).

Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.

Keywords: South Asians; dyslipidemia; endothelial function; omega-3 fatty acids; rosuvastatin.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Asia / ethnology
  • Asians*
  • Cross-Over Studies
  • Drug Therapy, Combination
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / ethnology
  • Dyslipidemias / physiopathology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Fluorobenzenes / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Lipids / blood
  • Male
  • Middle Aged
  • New York / epidemiology
  • Pyrimidines / therapeutic use*
  • Rosuvastatin Calcium
  • Sulfonamides / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Vasodilation / drug effects*
  • Vasodilator Agents / therapeutic use*

Substances

  • Fatty Acids, Omega-3
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids
  • Pyrimidines
  • Sulfonamides
  • Vasodilator Agents
  • Rosuvastatin Calcium